A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Xenia Bacinschi; Gabriel Cristian Popescu; Anca Zgura; Laurentia Gales; Anghel Rodica; Adriana Mercan; Dragos Serban; Bogdan Haineala; Letitia Toma; Laura Iliescu

doi:10.12659/MSM.936706

05 July 2022 : Clinical Research

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Xenia Bacinschi^1E, Gabriel Cristian Popescu^2C, Anca Zgura^1C*, Laurentia Gales^3F, Anghel Rodica^1A, Adriana Mercan^4D, Dragos Serban^5D, Bogdan Haineala^6B, Letitia Toma^4C, Laura Iliescu^4F

DOI: 10.12659/MSM.936706

Med Sci Monit 2022; 28:e936706

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Baseline characteristics of the study group.

Mean age	62.1±24.8 years
Sex ratio	Males: 194 (33.04%)Females: 263 (66.95%)
Mean HCV RNA	1 067 865±253.151 IU/mL
F2 fibrosis	83 patients among which
F3 fibrosis	185 patients among which
F4 fibrosis	315 patients among which
HCV relapse after liver transplantation	4 patients
Mean ALT levels	65.5±18.4 IU/mL
Mean bilirubin levels	1.2±0.4 mg/dL
Mean hemoglobin	12.7±2.8 g/dL
HCV – hepatitis C virus; ALT – alanine aminotranspherase.

Back to the Article

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Your Privacy